Performance of <sup>99m</sup> Tc-Sestamibi Single-Photon Emission Computed Tomography/Computed Tomography for Characterizing Renal Masses: Combined Results From a Prospective Scan-and-Resect Trial and Clinical Experience

<sup>99m</sup>Tc-sestamibi SPECT/CT is a novel method to effectively risk-stratify indeterminate renal masses. As with any nonsurgical method for renal mass characterization, there are potential false positives and false negatives, and those should be weighed carefully in shared decision-making with the patient to guide further evaluation and management.

Authors

Institutions

Publication Details

Journal
The Journal of Urology
Published
2025-12-23
DOI
https://doi.org/10.1097/ju.0000000000004911
Primary Topic
Renal cell carcinoma treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Performance of 99m Tc-Sestamibi Single-Photon Emission Computed Tomography/Computed Tomography for Characterizing Renal Masses: Combined Results From a Prospective Scan-and-Resect Trial and Clinical Experience

Benjamin L. Viglianti, Lilja B. Sólnes, Mohamad E. Allaf, Sara Sheikhbahaei et al.
The Journal of Urology
Renal cell carcinoma treatment
article

Performance of 99m Tc-Sestamibi Single-Photon Emission Computed Tomography/Computed Tomography for Characterizing Renal Masses: Combined Results From a Prospective Scan-and-Resect Trial and Clinical Experience

Benjamin L. Viglianti, Lilja B. Sólnes, Mohamad E. Allaf, Sara Sheikhbahaei, Reema Goel, Jorge D. Oldan, Steven P. Rowe, Michael A. Gorin, Ezra Baraban, Salikh Murtazaliev, Philip M. Pierorazio, Alireza Amindarolzarbi, Mehrbod S. Javadi, JI Epstein, Alex S. Baras, Alexa Meyer, Christian P. Pavlovich, Nirmish Singla, Hiten D. Patel, Basil Kauffman, McKenna Wood
article en

Abstract

<sup>99m</sup>Tc-sestamibi SPECT/CT is a novel method to effectively risk-stratify indeterminate renal masses. As with any nonsurgical method for renal mass characterization, there are potential false positives and false negatives, and those should be weighed carefully in shared decision-making with the patient to guide further evaluation and management.

The Journal of Urology
University of North Carolina at Chapel Hill (US), University of Maryland, Baltimore (US), University of Arizona (US), Penn Presbyterian Medical Center (US), Johns Hopkins University (US), University of Michigan (US), Johns Hopkins Medicine (US), University of Mississippi Medical Center (US), University of Chicago (US), LC Resources (United States) (US), Donald & Barbara Zucker School of Medicine at Hofstra/Northwell (US), Banner - University Medical Center Tucson (US), Regional Urology (US), Chinese Journal of Integrated Traditional and Western Medicine (CN), University of Pennsylvania (US), Icahn School of Medicine at Mount Sinai (US)
Peace, Justice and strong institutions
Openalex Percentile: Top 29%
Renal cell carcinoma treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.